The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2025 | A Phase I/II trial of liposomal annamycin with cytarabine for the treatment of AML
Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, discusses a Phase I/II combining liposomal annamycin with cytarabine for the treatment of acute myeloid leukemia (AML). Dr Papyannidis highlights promising complete remission rates and a manageable safety profile with no cardiotoxicity. This combination is being explored as a potential treatment in the relapsed setting for AML. This interview took place at the 19th International Symposium on Acute Leukemias (ISAL XIX) in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This combination is a very attractive one and it’s a Phase I/II trial with annamycin, which is a different formulation of doxorubicin in combination with cytarabine in the relapsed setting of acute myeloid leukemia. It is a study which has enrolled 22 patients, 20 were evaluable for efficacy. At the beginning there was a safety run-in cohort and then an expansion cohort and the results were very very exciting in terms of both safety and activity...
This combination is a very attractive one and it’s a Phase I/II trial with annamycin, which is a different formulation of doxorubicin in combination with cytarabine in the relapsed setting of acute myeloid leukemia. It is a study which has enrolled 22 patients, 20 were evaluable for efficacy. At the beginning there was a safety run-in cohort and then an expansion cohort and the results were very very exciting in terms of both safety and activity. In terms of safety, the safety profile seems to be very manageable. No cardiotoxicity was demonstrated and the tolerance to the drug was very very good. And in terms of efficacy, 50% of the patients in second line achieved a CR. This is a great response if we consider that unfortunately in the relapsed setting the rate of CR of AML is very very low and this can be a great beginning moving forward to the next trials again with the same drug and also in combination with other compounds.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
